$BAX · BAXTER INTERNATIONAL INC
Baxter International reported Q3 2026 results with sales of $2.976B (+5% reported and organic), GAAP diluted EPS of $0.57, and adjusted diluted EPS of $0.58. The company raised its full-year 2026 outlook for both revenue growth (4%–5% reported, 3%–4% organic) and adjusted EPS ($2.05–$2.15). The Board also declared a $0.01 quarterly dividend.
- Q3 worldwide sales of $2.976B grew 5% reported and organic, with growth across all segments and divisions.
- GAAP diluted EPS of $0.57 vs. $(0.10) a year ago; adjusted diluted EPS of $0.58.
- Operating income jumped 31% to $225M; operating margin expanded 150 bps to 7.6%.
- Full-year 2026 adjusted EPS guidance raised to $2.05–$2.15 (from $1.95–$2.15); organic sales growth outlook raised to 3%–4%.
- Board declared a quarterly cash dividend of $0.01 per share, payable January 4, 2027.
Extended-hours trading shows BAX at $26.00, up +2.12% vs. the regular close of $25.46, reflecting a positive initial reaction to the guidance raise and broad-based revenue growth.
Baxter delivered a clean beat-and-raise quarter with broad-based growth, aggressive debt reduction ($864M retired via $600M tender), and a reinstated dividend — signaling a turnaround gaining traction.
Baxter's 5% organic growth across all segments contrasts with mixed medtech peer results this quarter, while the $600M debt tender retiring $864M in obligations signals aggressive balance-sheet repair post-Kidney Care divestiture.
Forward-looking risks include the FDA Warning Letter on the Novum IQ large volume pump, supply chain disruptions, and potential failure to achieve expected operating efficiencies from the Kidney Care sale and Hill-Rom integration.